Claims
- 1. A compound comprising Formula I:
- 2. The compound of claim 1, wherein G2 is selected from the group represented by the Formula c and d.
- 3. The compound of claim 1, wherein G2 is selected from the group represented by the Formula e and f.
- 4. The compound of claim 1, wherein G1 is selected from the group represented by the Formula a.
- 5. The compound of claim 4, wherein G2 is selected from the group represented by the Formula c and d.
- 6. The compound of claim 5, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, —SO2R′, —NR′SO2R″, —SO2NR′R″,—COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 7. The compound of claim 6, wherein G2 is a group represented by the Formula c.
- 8. The compound of claim 7, wherein R1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, —OR′, —SO2R′, —NR′SO2R″, —COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 9. The compound of claim 7, wherein R1 is phenyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
- 10. The compound of claim 7, wherein R1 is pyridinyl which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
- 11. The compound of claim 7, wherein R1 is thienyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
- 12. The compound of claim 7, wherein R1 and R2, if adjacent, taken together with the carbons to which they are attached form an aromatic ring, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.
- 13. The compound of claim 5, wherein G2 is a group represented by the Formula c and A is pyridinyl.
- 14. The compound of claim 13, wherein R1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, —OR′, —SO2R′, —NR′SO2R″, —COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 15. The compound of claim 13, wherein R1 is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, —SO2R′, —NR′SO2R″, —SO2NR′R″, —NR′R″, or —COR′, and R′ and R″ are each independently hydrogen or lower alkyl.
- 16. The compound of claim 5, wherein G2 is a group represented by the Formula c and A is pyridiminyl, which is optionally substituted with halogen, alkyl, cyano, nitro, or alkoxy.
- 17. The compound of claim 16, wherein R1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, —OR′, —SO2R′, —NR′SO2R″, —COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 18. The compound of claim 4, wherein G2 is a group represented by the Formula e.
- 19. The compound of claim 18, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, —SO2R′, —NR′SO2R″, —SO2NR′R″, —NR′R″, or —COR′, R1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, —OR′, —SO2R′, —NR′SO2R″, —COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 20. The compound of claim 18, wherein A is phenyl optionally substituted lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, —SO2R′, —NR′SO2R″, —SO2NR′R″, —NR′R″, or —COR′; R′ and R″ are each independently hydrogen or lower alkyl; and R1 is phenyl optionally substituted with halogen, alkyl, cyano, nitro, or alkoxy.
- 21. The compound of claim 1, wherein G1 is a group represented by the Formula b1.
- 22. The compound of claim 21, wherein G2 is a group represented by the Formula c.
- 23. The compound of claim 22, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, —SO2R′, —NR′SO2R″, —SO2NR′R″, —NR′R″, or —COR′; and R′ and R″ are each independently hydrogen or lower alkyl.
- 24. The compound of claim 23, wherein R1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, —OR′, —SO2R′, —NR′SO2R″, —COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 25. The compound of claim 1, wherein G1 is selected from the group represented by Formula b2.
- 26. The compound of claim 25, wherein G2 is selected from the group represented by the Formula c.
- 27. The compound of claim 26, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, —SO2R′, —NR′SO2R″, —SO2NR′R″, —NR′R″, or —COR′; and R′ and R″ are each independently hydrogen or lower alkyl.
- 28. The compound of claim 27, wherein R1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, —OR′, —SO2R′, —NR′SO2R″, —COR′, and —NR′R″, and R′ and R″ are each independently hydrogen or lower alkyl.
- 29. The compound of claim 1, wherein the compound is selected from the group consisting of:
4-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic acid; 4′-fluoro-4-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic acid; 4′-fluoro-4-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-biphenyl-3-carboxylic acid; 2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-naphthalene-1-carboxylic acid; 2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-isopropoxy-benzoic acid; 2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-6-methyl-benzoic acid; 2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-pyridin-3-yl-benzoic acid; 5-methanesulfonyl-2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid; 4-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-biphenyl-3-carboxylic acid; 2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-5-thiophen-3-yl-benzoic acid; 5-bromo-2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid; [3-(1H-tetrazol-5-yl)-biphenyl-4-yl]-carbamic acid 5-phenyl-benzofuran-2-ylmethyl ester; [2-(1H-tetrazol-5-yl)-phenyl]-carbamic acid 5-phenyl-benzofuran-2-ylmethyl ester; 2-chloro-6-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-benzoic acid; 2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-naphthalene-1-carboxylic acid; 2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-methanesulfonylamino-benzoic acid; [2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-phenyl]-acetic acid; 2-[2-(biphenyl-4-yloxy)-ethoxycarbonylamino]-6-chloro-benzoic acid; and 2-chloro-6-(5-pyrimidin-5-yl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid.
- 30. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in admixture with at last one pharmaceutically acceptable carrier.
- 31. A method of treating a subject with a disease state that is alleviated with an IP antagonist, with an effective amount of one of more compounds of claim 1.
- 32. The method of treatment of claim 31, wherein the disease state comprises disorders of the urinary tract, pain, inflammation, respiratory states, edema formation or hypotensive vascular diseases.
- 33. The method of treatment of claim 32, wherein the disease state comprises bladder disorders associated with bladder outlet obstruction and urinary incontinence conditions.
- 34. The method of treatment of claim 32, wherein the disease state comprises pain.
- 35. The method of treatment of claim 32, wherein the disease state comprises inflammation.
- 36. The method of treatment of claim 32, wherein the disease state comprises respiratory states form allergies and asthma.
- 37. A process for preparing a compound as claimed in claim 1, which process comprises:
esterification of the compounds having a general Formula 2 or 3: 39wherein n, R1 and R2 are as defined in claim 1, acylation with phosgene, followed by reaction with a compound of general Formula 140wherein G1 is as defined in claim 1, and hydrolysis, to provide a compound of the general Formula Ia or Ib 41wherein n, G1, R1, and R2 are as defined in claim 1.
- 38. A process for preparing a compound as claimed in claim 1, which process comprises:
acylation with phosgene of a compound of general Formula cm or co, 42wherein n, R1 and R2 are as defined herein, followed by reaction with a compound of general Formula 143wherein G1 is as defined in claim 1, and treatment with azide to provide a compound of general Formula Ic or Id 44wherein n, G1, R1, and R2 are as defined in claim 1.
CROSS REFERENCE TO RELATED INVENTIONS
[0001] This application claims benefit under Title 35 U.S.C. 119(e) of U.S. Provisional Applications No. 60/272,872 filed Mar. 2, 2001, and No. 60/312,559 filed Aug. 15, 2001, all applications are hereby incorporated by reference in its entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60272872 |
Mar 2001 |
US |
|
60312559 |
Aug 2001 |
US |